Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sotera Health ( (SHC) ) has provided an announcement.
On July 23, 2025, Sterigenics U.S., LLC, a subsidiary of Sotera Health Company, agreed to a $34 million settlement to resolve 129 ethylene oxide claims related to its former Willowbrook, Illinois facility. This settlement, which includes claims set for trials in late 2025 and early 2026, is contingent upon several conditions, including full claimant participation and court approval. Sterigenics denies any liability, emphasizing that the settlement is not an admission of fault or safety hazards posed by the facility’s emissions.
The most recent analyst rating on (SHC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.
Spark’s Take on SHC Stock
According to Spark, TipRanks’ AI Analyst, SHC is a Neutral.
Sotera Health’s overall stock score is driven by solid financial performance and a positive earnings outlook, tempered by high leverage and valuation concerns. Technical indicators suggest potential bearish trends, while achievements like FDA clearance for new products are positive developments.
To see Spark’s full report on SHC stock, click here.
More about Sotera Health
Sotera Health Company operates in the health sector, primarily focusing on sterilization services through its subsidiary, Sterigenics U.S., LLC. The company is involved in providing sterilization solutions, which are crucial for ensuring the safety and efficacy of medical products.
Average Trading Volume: 1,171,735
Technical Sentiment Signal: Sell
Current Market Cap: $3.36B
For a thorough assessment of SHC stock, go to TipRanks’ Stock Analysis page.